Literature DB >> 17988992

Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.

Hirokazu Kanegane1, Sayaka Watanabe, Keiko Nomura, Gang Xu, Etsuro Ito, Toshio Miyawaki.   

Abstract

Children with Down syndrome (DS) have an approximately 20-fold higher incidence of leukemia than unaffected children, and most leukemia cases with DS present as acute megakaryocytic leukemia (AMKL). At least 10% of neonates with DS develop transient myeloproliferative disorder (TMD), and 20% to 30% of patients with TMD develop AMKL. Mutations in the GATA1 gene are identified not only in AMKL patients but also in TMD patients; however, sequential analysis of GATA1 is not often performed in the same patients. We describe a child with DS who developed TMD followed by AMKL and have identified different mutations in the GATA1 gene during the course of TMD and AMKL. Distinct clones were associated with the development of TMD and AMKL in this patient.

Entities:  

Mesh:

Year:  2007        PMID: 17988992     DOI: 10.1532/IJH97.07058

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

Review 1.  The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.

Authors:  B Lange
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

2.  Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.

Authors:  Akira Shimada; Gang Xu; Tsutomu Toki; Hirokazu Kimura; Yasuhide Hayashi; Etsuro Ito
Journal:  Blood       Date:  2004-01-01       Impact factor: 22.113

Review 3.  GATA transcription factors in hematologic disease.

Authors:  Alan B Cantor
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

4.  Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.

Authors:  Gang Xu; Koji Kato; Tsutomu Toki; Yoshihiro Takahashi; Kiminori Terui; Etsuro Ito
Journal:  J Pediatr Hematol Oncol       Date:  2006-10       Impact factor: 1.289

Review 5.  Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21.

Authors:  Alvin Zipursky
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

6.  Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages.

Authors:  D I Martin; L I Zon; G Mutter; S H Orkin
Journal:  Nature       Date:  1990-03-29       Impact factor: 49.962

7.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Authors:  Johann K Hitzler; Joseph Cheung; Yue Li; Stephen W Scherer; Alvin Zipursky
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

8.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

9.  Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor.

Authors:  R Calligaris; S Bottardi; S Cogoi; I Apezteguia; C Santoro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

10.  Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.

Authors:  Jürgen Groet; Suzanne McElwaine; Monica Spinelli; Andrea Rinaldi; Ingo Burtscher; Claire Mulligan; Afua Mensah; Simona Cavani; Franca Dagna-Bricarelli; Giuseppe Basso; Finbarr E Cotter; Dean Nizetic
Journal:  Lancet       Date:  2003-05-10       Impact factor: 79.321

View more
  2 in total

1.  Transient abnormal myelopoiesis in a cytogenetically normal neonate.

Authors:  Kentaro Yanase; Keisuke Kato; Nobuko Katayama; Yoko Mouri; Chie Kobayashi; Junko Shiono; Masakazu Abe; Ai Yoshimi; Kazutoshi Koike; Jun-Ichi Arai; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2010-09-23       Impact factor: 2.490

2.  Transient abnormal myelopoiesis in a phenotypically normal newborn with polyclonal trisomy 21.

Authors:  Francesco Corazza; Annalisa Astolfi; Virginia Libri; Monica Franzoni; Salvatore Serravalle; Rosina Alessandroni; Fraia Melchionda; Andrea Pession
Journal:  Int J Hematol       Date:  2014-04-26       Impact factor: 2.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.